Role of folate receptor and CD44 in targeting of docetaxel and paclitaxel fabricated conjugates for efficient cancer therapy
Amol Tatode, Pranav Agrawal, Jayshree Taksande, Mohammad Qutub, Tanvi Premchandani, Milind Umekar, Kishor Danao
Abstract
A novel target folate receptor and CD44 receptor are deliberated for effective as chemotherapeutic agents. Usually, these receptors are play a vital role in the functional condition such as cell adhesion, healing and inflammation process. Thus, to treat cancerous cell is most difficult by traditional method can be most easily treated with the use of folic acid and hyaluronic acid-linked chemotherapeutics. Also, the various problems associated with Paclitaxel and Docetaxel like inability to deliver at specific target, affection towards healthy cells, poor aqueous solubility, side effects and acquired drug resistance can be minimized with the use of this targeting technique. In recent years, various studies have been ongoing on minimizing the problems associated with the delivery of docetaxel and paclitaxel, and targeting therapy is one of them. This review gives a clear picture of the concept of targeting therapy for the efficient delivery of docetaxel and paclitaxel using folic and hyaluronic acid conjugates. • The article comments on common functioning of the CD44 receptors and folate receptors. • Role of the CD44 receptors and folate receptors in cancer pathogenesis. • Focuses on the CD44 receptors and folate receptors over-expression, as a possible target for the conjugated docetaxel and paclitaxel delivery in the treatment and management of malignancy. • This review gives a clear picture of the concept of targeting therapy for the efficient delivery of docetaxel and paclitaxel using folic and hyaluronic acid conjugates.